Cordyceps Sunshine Biotech Holdings (RAJAF) Accounts Payables (2020 - 2025)

Cordyceps Sunshine Biotech Holdings' Accounts Payables history runs 5 years deep, the most recent figure standing at $16640.0 for Q4 2025.

• In Q4 2025, Accounts Payables fell 40.76% year-over-year to $16640.0; the TTM figure through Dec 2025 stood at $16640.0 (down 40.76% YoY), while the FY2025 annual figure was $16640.0, down 40.76% from the prior year.
• Accounts Payables was $16640.0 for Q4 2025 at Cordyceps Sunshine Biotech Holdings, down from $28088.0 in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $1.4 million in Q3 2023 to a low of $9506.0 in Q4 2023.
• Historically, Accounts Payables has averaged $318419.8 across 4 years, with a median of $28088.0 in 2024.
• The sharpest annual moves came in 2021 and 2025: Accounts Payables soared 90709.76% in 2021, then tumbled 40.76% in 2025.
• A 4-year view of Accounts Payables shows it stood at $111696.0 in 2021, then slumped by 91.49% to $9506.0 in 2023, then jumped by 195.48% to $28088.0 in 2024, then plunged by 40.76% to $16640.0 in 2025.
• The last three Accounts Payables figures came in at $16640.0 (Q4 2025), $28088.0 (Q4 2024), and $9506.0 (Q4 2023), per Business Quant data.